Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians
- 1 February 2003
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 13 (2) , 97-105
- https://doi.org/10.1097/00008571-200302000-00006
Abstract
Polymorphisms in the TPMT gene open reading frame (ORF) are associated with reduced TPMT activity. Variable number tandem repeats (VNTR*3 to VNTR*9) in the promoter region of the gene consisting of combinations of Type A, B and C repeat units, may modulate TPMT activity. Here we present the allele frequencies of genetic modifiers of TPMT activity in a British Asian population, as well as the concordance between intermediate TPMT activity and ORF and VNTR genotypes in a predominantly Caucasian population. VNTR type and ORF mutations were determined in two selected TPMT activity ranges, intermediate activity (4-8 U, 108 patients), normal (12-15 U, 53 patients) and in 85 British Asians. In British Asians, TPMT*3C was the prevalent mutant allele (four heterozygotes). One patient was heterozygous for TPMT*3A. Overall VNTR frequencies did not differ from Caucasians. Three new VNTR alleles were designated VNTR*6c, VNTR*6d, and VNTR*7c. Forty-one percent of patients with intermediate activity were heterozygous for a TPMT ORF mutation (3A, 2B, 1C). Marked linkage disequilibrium was noted between VNTR*6b - TPMT*3A (D' = 1), VNTR*4b - TPMT*3C (D' = 0.67) and VNTR*6a - TPMT*1 (D' = 1) alleles. As a result, significant differences (P < 0.05) in the distribution of Type A, B or the total number of repeats summed for both alleles, were found between the ORF heterozygous intermediate activity group and the wild-type intermediate or normal activity groups. No significant difference was found between the two wild-type groups. Our results suggest that TPMT gene VNTRs do not significantly modulate enzyme activity.Keywords
This publication has 38 references indexed in Scilit:
- Polymorphism of the thiopurine S-methyltransferase gene in African- AmericansHuman Molecular Genetics, 1999
- Clinical Implications of Thiopurine Methyltransferase-Optimization of Drug Dosage and Potential Drug InteractionsTherapeutic Drug Monitoring, 1998
- Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity.Journal of Clinical Investigation, 1998
- Detection of known and new mutations in the thiopurineS-methyltransferase gene by single-strand conformation polymorphism analysisHuman Mutation, 1998
- Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*Clinical Pharmacology & Therapeutics, 1997
- Individualizing Therapy with 6-Mercaptopurine and 6-Thioguanine Related to the Thiopurine Methyltransferase Genetic PolymorphismTherapeutic Drug Monitoring, 1996
- A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.Proceedings of the National Academy of Sciences, 1995
- Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphismClinical Pharmacology & Therapeutics, 1989
- Human kidney thiopurine methyltransferase purification and biochemical propertiesBiochemical Pharmacology, 1983
- Metabolism of Thiopyrimidines and ThiopurinesJournal of Biological Chemistry, 1963